Organisation paid for research Program year 2025 Source: CMS Open Payments

Atlantic Health System

Neither a doctor nor a teaching hospital

Research payments

$670,823

118 payments

Through program year 2025, Atlantic Health System is reported as receiving $670,823 in research payments, across 118 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$27,012	12
2024	Research	$63,278	29
2023	Research	$61,112	8
2022	Research	$7,160	3
2021	Research	$183,583	13
2020	Research	$253,927	34
2019	Research	$74,750	19

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $238,556 10 payments
GlaxoSmithKline, LLC. $130,960 13 payments
Genentech, Inc. $65,866 16 payments
Covidien LP $41,145 6 payments
MorphoSys AG $23,535 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $23,155 21 payments
Provepharm Inc. $22,313 1 payment
QOL Medical, LLC $19,755 1 payment
W. L. Gore & Associates, Inc. $18,231 17 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $17,670 2 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Placebo-controlled, Multi-site Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COIVD-19 Treatment $139,429 1 payment
A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib $116,884 4 payments
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer $66,536 4 payments
Blink $41,145 6 payments
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC $32,393 4 payments
A phase IIa, multicenter, open-label study to Assess the Safety and Efficacy of the Combination BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Cancer $29,700 2 payments
A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma $23,535 4 payments
Pvp-Ic1901 $22,313 1 payment
QOL Pediatric Sucraid $19,755 1 payment
MRD Monotherapy, combination of VSV GP w antiPD1 $18,492 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.